Glucoprivation activates neurons in the perifornical hypothalamus (PeH) and in the rostral ventrolateral medulla (RVLM), which results in release of adrenaline. The current study aimed to establish (i) whether neuroglucoprivation in the PeH or in the RVLM elicits adrenaline release in vivo; and (ii) whether direct activation by glucoprivation or orexin release in the RVLM modulates the adrenaline release. Neuroglucoprivation in the PeH or RVLM was elicited by microinjections of 2-deoxy-D-glucose or 5-thio-Dglucose in anesthetized, euglycemic, rats. We found that inhibition of neurons in the PeH abolished the increase in adrenal sympathetic nerve activity (ASNA) to systemic glucoprivation. Secondly, glucoprivation of neurons in the PeH increased ASNA. Thirdly, in vivo or in vitro glucoprivation did not affect the activity of RVLM adrenal premotor neurons. Finally, blockade of orexin receptors in the RVLM abolished the increase in ASNA to neuroglucoprivation in the PeH. The evoked changes in ASNA were directly correlated to levels of plasma metanephrine, but not to normetanephrine. These findings suggest that orexin release modulates the activation of adrenal presympathetic neurons in the RVLM.
Introduction
Glucoprivation is a metabolic challenge capable of eliciting adrenaline release, an important mechanism for restoration of normal blood sugar levels. Additionally, neuroglucoprivation produced by 2-deoxy-D-glucose (2-DG) is used as an experimental tool to study glucoregulatory neurons (1) (2) (3) (4) . Previous findings suggest that adrenaline release in response to glucoprivation involves activation of neurons in the perifornical hypothalamus (PeH) and rostral ventrolateral medulla (RVLM). Systemic glucoprivation using 2DG excites RVLM sympathetic premotor neurons (5; 6) and orexinergic neurons (7) in the PeH (8) . Additionally, neurotropic viruses injected into the adrenal gland transsynaptically label neurons in both the RVLM (9) and PeH (10) . Disinhibition of perifornical neurons produces an increase in endogenous glucose production in the liver, which is mediated by the autonomic nervous system (11) . However, it remains unknown as to whether intrinsic glucose sensitivity or projections from hypothalamic glucose-sensitive neurons (4; 12; 13) plays an important role in the excitation of RVLM adrenal premotor neurons in response to glucoprivation. In particular, if the responses evoked in RVLM neurons are modulated by orexinergic inputs (14; 15) .
In this study, we hypothesize that perifornical hypothalamic neurons respond to neuroglucoprivation, and elicit adrenaline release by orexinergic activation of sympathetic premotor neurons in the RVLM. To test this hypothesis, we used a combination of in vivo and in vitro electrophysiological techniques to first examine the role played by neurons in the PeH in driving adrenal sympathetic nerve activity (ASNA).
We then demonstrate for the first time that these effects are independent of any intrinsic sensitivity of neurons in the RVLM to glucoprivation, and that the activation of orexin receptors in the RVLM modulates the adrenal sympathoexcitatory responses. was maintained at a level in which paw pinch produced minimal changes in blood pressure (≤10 mmHg). Blood glucose was measured by withdrawing a drop of ar blood from the femoral artery and applied to a glucometer (Optium Xceed; Medisense; Abbott Laboratories, Bedford, USA), as previously described (5) .
Methods

Adrenal sympathetic nerve recording
The right adrenal sympathetic nerve was prepared for recording via a retroperitoneal approach. Fibers emerging from the ganglion projecting towards the adrenal gland were carefully dissected free from connective tissue and fat. The fibers were tied together using 10-0 surgical nylon, cut distally, and mounted on bipolar silver wire electrodes.
The nerve was covered with paraffin oil or embedded in a silicone elastomer (Kwik-Cast Sealant, WPI, Sarasota, FL, USA). Adrenal sympathetic nerve activity (ASNA) was amplified (x10000; Grass 7P5B, Quincy, MA, USA) filtered (100 Hz-3 kHz), and sampled at 6 kHz using a CED Power1401 (Cambridge Electronic Design, UK) with Spike2 v7.02 software. ASNA was rectified and integrated (τ=1s) prior to analysis. All neurograms were normalized with reference to the resting level prior to stimulus (100%) after subtraction of the noise (0%), determined post mortem or after clonidine (200 µg*kg -1 , i.v.; Sigma-Aldrich). Experiments were not included for analysis if the ratio of pre-/post-ganglionic ASNA was higher than 50%, verified by intravenous hexamethonium (40 mg*kg -1 , Sigma-Aldrich) at the end of the experiments.
Measurement of blood catecholamines
Due to the rapid degradation of catecholamines, we measured plasma levels of metanephrines (16) . Plasma (0.2 ml) was extracted from blood (0.5 ml), withdrawn from the femoral arterial cannula, to determine the levels of metanephrine and normetanephrine. Plasma metanephrines were assayed by liquid chromatography tandem mass spectrometry, modified from the method of Whiting (17) . Heparinized plasma samples had deuterated internal standards for each analyte that were added prior to solid phase extraction using weak cation exchange. Extracted samples were evaporated to dryness, reconstituted and derivatised using cyanoborohydride and acetaldehyde prior to chromatographic separation and mass spectrometric detection using multiple reactions monitoring (model 6460 Agilent Technologies, Mulgrave, Australia).
Location of the PeH and RVLM
The perifornical hypothalamus (PeH) was located using stereotaxic coordinates (18).
These were: 2.9-3.4 mm caudal to Bregma, 1.1-1.3 mm lateral to the midline, 8.6-8.7 mm ventral to the dorsal surface.
RVLM adrenal sympathetic premotor neurons are mingled with cardiovascular premotor neurons (5). Hence, the RVLM was identified by extracellular recording of cardiovascular sympathetic premotor neurons, which were inhibited by phenylephrine Pontamine Sky Blue in 0.5 M sodium acetate. Extracellular potentials were recorded using a window discriminator and amplifier (x10000; 400-4000 Hz; Fintronics, Orange, USA). RVLM sympathetic premotor neurons were found at: +0.1 rostral to -0.3mm caudal, 0.1-0.3 mm medial, and 0.1-0.3 mm ventral to the caudal pole of the facial nucleus.
Glucoprivation and Microinjections
All experimental procedures were conducted following establishment of a euglycemic baseline (4.8-7.0 mM; average: 6.1±0.1 mM, N=60 Neuroglucoprivation was elicited by microinjections of 2DG (0.2-20 mM) or 5-thio-Dglucose (5TG; 0.6-600 mM; Sigma-Aldrich), using doses based on previous reports (2; 20). Perifornical neurons were permanently inhibited by the GABA A agonist muscimol (4 mM; Sigma-Aldrich) or disinhibited by the GABA A antagonist bicuculline (1 mM; SigmaAldrich). Note that these agents were used primarily to inhibit or activate hypothalamic neurons, and also to determine the role of their respective GABAergic inputs in glucose homeostasis. Orexin A (0.1-10 mM; Sigma-Aldrich) was microinjected into the RVLM using doses based on a previous study (21). Orexin receptors in the RVLM were blocked using the non-selective antagonist TCS1102 (5 mM; Tocris), diluted in 50% dimethyl sulfoxide (DMSO, Sigma-Aldrich) using a dose based on a previous report (22).
Histology
At the end of the experiments, animals were perfused with NaCl 0.9% w/v followed by 10 % formalin. Brains were removed, fixed in formalin overnight, and cut with a vibratome in 100 µm coronal sections. Sections were mounted onto gelatin-subbed slides for identification of the injection sites. Sections were examined under epifluorescence to locate the fluorescent bead deposits. Recordings were performed at room temperature in the recording chamber of an
Olympus microscope superfused at 1.5-2 ml/min with carbogen-bubbled aCSF.
Tracer-labeled neurons were identified under epi-fluorescence: CTB-filled neurons lying ventral to nucleus ambiguus and lateral to the inferior olive were identified as RVLM 
Data analysis
The effects of 2DG were assessed by comparing the holding current and the synaptic current frequency, averaged over 50 seconds prior to drug administration (baseline), to the mean over the last 50 seconds of drug perfusion (drug). The dose of 2DG (5 mM) was selected based on previous reports (4; 13). Experimental protocols:
1. ASNA was plotted against levels of circulating metanephrines to establish the relationship between nerve discharge and adrenaline release. Two samples were taken per experiment: during the resting condition when ASNA recordings had been stable for 10 minutes and ~6-10 minutes after intravenous injection of 2DG.
2. ASNA responses to intravenous 2DG were tested after microinjection of muscimol or bicuculline into the PeH to determine the role of GABAergic drive to perifornical neurons in adrenal sympathetic responses to glucoprivation. 2DG was also microinjected after bicuculline to determine its pharmacological effect in the absence of inhibitory tone to perifornical neurons. Lumbar sympathetic nerve activity (LSNA) and ASNA were recorded to determine if sympathetic responses to glucoprivation are differentially regulated.
3. The effects of focal PeH neuroglucoprivation on ASNA were determined by bilateral microinjections of 2DG or 5TG, according to previous reports (2; 20).
4. ASNA was compared before and after bilateral microinjections of 2DG into the RVLM to determine whether adrenal RVLM sympathetic premotor neurons were responsive to glucoprivation in vivo. Subsequent intravenous injection of 2DG confirmed that the ASNA responses were not dependent on a direct effect on RVLM neurons.
5. The intrinsic sensitivity of RVLM sympathetic premotor neurons to glucoprivation was also tested in vitro. Following the establishment of stable recordings in aCSF containing 2 mM glucose slices were perfused for 300 s in aCSF containing 5 mM 2DG (4; 13).
The effect of glucoprivation on membrane potential and spontaneous discharge frequency was assessed by comparing measurements made over the final 50 s of the control period to the final 50 s of 2DG application. Membrane resistance was monitored by measuring changes in membrane potential evoked by hyperpolarizing currents (-40 pA, 1 s) every 30 seconds and calculated using Ohm's Law (4). The average membrane resistance measured over the final 3 steps of the control period was compared to data measured at the corresponding periods of 2DG administration. Neuronal excitability was assessed by comparing the number of action potentials generated by depolarizing current pulses (20 pA, 3 s) every 60 seconds (13). As described above data were averaged from the final 3 consecutive depolarizing steps in the control and 2DG
periods. Voltage clamp ramps from 0 to -140 mV from a holding potential of -60 mV were performed to assess current-voltage relationships (4).
6. These experiments determined whether orexinergic activation of premotor neurons in the RVLM mediates the adrenal sympathoexcitatation to glucoprivation. Orexin receptors were activated using microinjections of orexin A at different doses before and after microinjection of the antagonist TCS1102. Adrenal sympathoexcitation in response to microinjection of 2DG into the PeH was also tested following microinjections of TCS1102 or vehicle into the RVLM.
Results
Correlation of ASNA and plasma metanephrines
At rest, the levels of blood glucose were 6.0±0.1 mM (N=8); systemic glucoprivation (2DG, 250 mg/kg) increased the concentration of plasma metanephrine (3.4±0.7 vs.
18.4±4.4 pmol*l 
Role of perifornical neurons in driving sympathetic responses to glucoprivation
ASNA responses to systemic 2DG (250mg/kg) in intact rats were compared to those measured following inhibition of perifornical neurons with microinjections of muscimol (4 mM). Prior to 2DG administration, blood glucose was at 6.0±0.2 mM (N=14).
Systemic glucoprivation increased ASNA (165±12%, P<0.001, N=17), which peaked at ~6 min ( ) reduced only LSNA (Fig. 2G&H) .
Effects of neuroglucoprivation in the PeH
Perifornical focal microinjection of 2DG or 5TG evoked adrenal sympathoexcitation (Fig.   3 ). Resting levels of blood glucose prior to 2DG and 5TG administration were 6.6±0.3 mM (N=10) and 6.7±0.1 mM (N=6), respectively. Bilateral microinjections of 2DG into the PeH (20) dose-dependently augmented ASNA (175±10%, P<0.001, N=10). Bilateral 5TG also increased ASNA (145±11%, P<0.01, N=6). The increases in ASNA in response to either 2DG or 5TG were similar in magnitude (P>0.05, N=6), and correlated with the increases in arterial blood glucose (Fig. 3D&F) .
Glucoprivation of RVLM sympathetic premotor neurons in vivo
At a blood glucose baseline of 6.4±0.2 mM (N=6), bilateral microinjections of 2DG (2 mM) into the RVLM evoked no effect on ASNA (90±12%, P=0.33, N=6; Fig. 4 ).
Subsequent systemic injection of 2DG (250 mg/kg; i.v.) increased ASNA (162±18%,
P<0.001, N=6).
Glucoprivation of RVLM sympathetic premotor neurons in vitro
16 sympathetic premotor neurons were recorded in 11 brainstem slices from 5 rats (Fig. 5) . In all but three cases current-and voltage-clamp data were obtained from the same neurons. In no case did 2DG evoke any clear effect on any parameter recorded.
In current clamp the resting membrane potential was -52. 
P<0
.001, N=6) produced by microinjection of 2DG into the PeH (Fig. 6E-G ).
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Discussion
The principal finding in this study is that orexin modulates the activity of RVLM adrenal sympathetic premotor neurons resulting in excitation of adrenal chromaffin cells. We showed that local glucoprivation or disinhibition of PeH neurons increased ASNA while inhibition of PeH neurons abolished the ASNA response following systemic glucoprivation. Conversely, glucoprivation of perifornical neurons subsequent to activation by the GABA A antagonist bicuculline reduced the adrenal sympathoexcitatory response. In addition, local neuroglucoprivation in the RVLM failed to activate premotor neurons in vivo or in vitro suggesting that RVLM neurons are not intrinsically glucose sensitive. Finally, ASNA was directly correlated with plasma metanephrine levels but not normetanephrine levels confirming that adrenal sympathoexcitation coincides with adrenaline release into the circulation. The ASNA, noradrenaline, and adrenaline responses to glucoprivation noted in our study were consistent with previous reports of the effects of glucoprivation on sympathetic preganglionic neurons (24).
In this study, microinjection of 2DG/5TG or bicuculline into the PeH increased ASNA, whereas microinjection of the GABA A agonist muscimol into the PeH abolished the ASNA response to systemic injection of 2DG. Reports by others have shown that 2DG exerts a glucomimetic inhibition of orexinergic and GABAergic perifornical neurons (4; 13; 25). Thus, direct excitation of perifornical neurons by 2DG in our study is unlikely to be the mechanism underlying the increase in ASNA. Alternatively, adrenal sympathoexcitation could result from disinhibition of perifornical neurons that receive GABAergic drive (11) . Orexinergic neurons express GABA receptors (26), and may receive inhibitory inputs from adjacent interneurons (25) or from the ventromedial hypothalamus (27; 28). In our study, microinjection of 2DG into the PeH decreased the ASNA response evoked by prior administration of bicuculline into the same site, confirming the glucomimetic inhibitory effect of 2DG seen in vitro (4; 13; 25). One interpretation of this result is that 2DG acts at some location adjacent to the PeH. If so, this could explain the onset (~1min) of the ASNA response to microinjection of 2DG into the PeH. Consistent with this notion, are previous observations that injection of 2DG into the ventromedial hypothalamus (1) or into the ventrolateral portion of the lateral hypothalamus (29) elicits glucoprivic effects resulting in adrenaline release and adrenal sympathoexcitation, respectively. While we have demonstrated that 2DG can exert inhibitory effects on PeH neurons, consistent with previous observations in vitro (4; 13; 25), the inevitable conclusion is that in our in vivo study an excitatory response predominates.
Blockade of orexin receptors in the RVLM by microinjection of TCS1102 eliminated the adrenal sympathoexcitatory response to injections of 2DG into the PeH. The dose of the orexin antagonist used was sufficient to block the effects of microinjection of orexin into the RVLM on ASNA. Based on the density of the extracellular milieu (30) and histology, our injections extended for ~400 µm, and so targeted the majority of C1 neurons (6).
The ASNA response to microinjection of orexin into the RVLM concurs with previous observations (21). Glucoprivation activates slow-conducting (<1 m/s) RVLM adrenal premotor neurons, which are intermingled with the cardiovascular premotor neurons (5).
The slow-conducting axons suggest that they are C1 catecholaminergic cells (31).
Glucoprivation also elicits Fos expression (6) and phosphorylation (32) in C1 neurons.
Orexinergic neurons project to the C1 region of the RVLM (14; 15) and their terminals make close appositions with C1 neurons (33). Moreover, neurotoxic ablation of C1 neurons eliminates the glucoregulatory response to 2DG (34). Together, the evidence suggests that orexinergic activation of adrenal sympathetic premotor neurons modulates the adrenal sympathoexcitatory response to glucoprivation. Although previous studies (35; 36) have shown that selective glucoprivation of hindbrain neurons increases blood glucose; local application of 2DG failed to activate the RVLM adrenal premotor neurons. Thus, hindbrain glucose-sensitive neurons (6; 37) are presumably located outside the RVLM, but project to (38) and excite the adrenal C1 neurons.
The present study has explored the neural pathway(s) that relay the adrenal sympathoexcitatory response to neuroglucoprivation. We used 2DG as a glucoprivic agent because it allows the investigator to produce localized glucoprivation when injected into the brain parenchyma. Importantly, systemic 2DG produces secretion of adrenaline, glucagon, cortisol, and growth hormone (39; 40). Since 2DG is also detected by most glucometers, we were unable to determine blood glucose changes after systemic 2DG. Nonetheless, glucoprivation elicits hyperglycemia via activation of glycogenolysis and gluconeogenesis in the liver (3; 11; 41). General anesthesia was essential for measurement of ASNA and eliminated the influence of stress, respiration, or body temperature (42-44). Anesthesia can alter neural metabolism and modulate glycemia and it is known that intraperitoneal urethane causes hyperglycemia (45).
However, under the conditions of our experiment we found that urethane produced normoglycemic animals (~6.1 mM). Comparison of different methods for determining catecholamine levels indicated that plasma metanephrines determined by mass spectrometry is the most reliable method (16) . Finally, the age of rat pups used the in vitro experiments correspond to previous electrophysiological studies (46) and the catecholaminergic neurons are likely to be mature and functional (47).
In conclusion, our findings suggest a key role for orexin in modulating the sympathetic drive to the adrenal chromaffin cells during glucoprivation. It is possible that during arousal orexin changes the electrophysiological properties of adrenal premotor neurons facilitating adrenaline release in response to glucopenia -a mechanism that may be compromised when hypoglycemia unawareness develops in response to recurrent glucoprivation (3). Page 34 of 36 Diabetes
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